Showing 4201-4210 of 5328 results for "".
- First-Ever Molecular Study Shows African American Skin Reacts Differently to ADhttps://practicaldermatology.com/news/first-ever-molecular-study-shows-african-american-skin-reacts-differently-to-ad/2457612/African Americans are known to have greater treatment challenges with atopic dermatitis than European Americans and require higher doses of some medications to get relief, and now a new study suggests that differences in the molecular profile of their skin may be the reason. About 19 perc
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Allergan's SkinMedica Tackles Blue Light and More with New LUMIVIVE Systemhttps://practicaldermatology.com/news/skinmedica-tackles-blue-light-and-more-with-new-lumivie-system/2457620/Allergan is launching the SkinMedica LUMIVIVE System, with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's repair process at night for 24-hour protection and revital
- Canfield Scientific Acquires Leading German Dermoscopy Company VISIOMED AGhttps://practicaldermatology.com/news/canfield-scientific-acquires-leading-german-dermoscopy-company-visiomed-ag/2457621/Canfield Scientific has acquired German company VISIOMED AG, which designs and manufactures dermoscopy systems. The resulting business has decades of experience in aesthetic documentation, 3D imaging, clinical photography, and reflected light microscopy leading to more choices and services for cu
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- Carpe: New Antiperspirant Twice As Effective As "Extra Strength"https://practicaldermatology.com/news/carpe-new-antiperspirant-twice-as-effective-as-extra-strength/2457623/Carpe’s newly launched underarm antiperspirant has been demonstrated to reduce sweat twice as effectively as the US legal standard for extra strength antiperspirants, the company says. While federal regulation requires that an extra strength antiperspirant demonstrate at least a 30% r
- AbbVie to Present New Data at 27th EADV Congresshttps://practicaldermatology.com/news/abbvie-to-present-new-data-at-27th-eadv-congress/2457625/AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-1
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity